GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MEI Pharma Inc (NAS:MEIP) » Definitions » Pretax Margin %

MEI Pharma (MEI Pharma) Pretax Margin % : % (As of Mar. 2024)


View and export this data going back to 2003. Start your Free Trial

What is MEI Pharma Pretax Margin %?

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. MEI Pharma's Pre-Tax Income for the three months ended in Mar. 2024 was $-9.13 Mil. MEI Pharma's Revenue for the three months ended in Mar. 2024 was $0.00 Mil. Therefore, MEI Pharma's pretax margin for the quarter that ended in Mar. 2024 was %.

The historical rank and industry rank for MEI Pharma's Pretax Margin % or its related term are showing as below:

MEIP' s Pretax Margin % Range Over the Past 10 Years
Min: -2470.22   Med: -133.8   Max: 39.18
Current: 39.18


MEIP's Pretax Margin % is ranked better than
94.42% of 1021 companies
in the Biotechnology industry
Industry Median: -154.03 vs MEIP: 39.18

MEI Pharma Pretax Margin % Historical Data

The historical data trend for MEI Pharma's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MEI Pharma Pretax Margin % Chart

MEI Pharma Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Pretax Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -342.18 -169.95 -118.71 -133.80 -65.22

MEI Pharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -261.93 -688.33 86.33 - -

Competitive Comparison of MEI Pharma's Pretax Margin %

For the Biotechnology subindustry, MEI Pharma's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MEI Pharma's Pretax Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MEI Pharma's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where MEI Pharma's Pretax Margin % falls into.



MEI Pharma Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

MEI Pharma's Pretax Margin for the fiscal year that ended in Jun. 2023 is calculated as

Pretax Margin=Pre-Tax Income (A: Jun. 2023 )/Revenue (A: Jun. 2023 )
=-31.838/48.816
=-65.22 %

MEI Pharma's Pretax Margin for the quarter that ended in Mar. 2024 is calculated as

Pretax Margin=Pre-Tax Income (Q: Mar. 2024 )/Revenue (Q: Mar. 2024 )
=-9.127/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MEI Pharma  (NAS:MEIP) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.


MEI Pharma Pretax Margin % Related Terms

Thank you for viewing the detailed overview of MEI Pharma's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


MEI Pharma (MEI Pharma) Business Description

Traded in Other Exchanges
Address
11455 El Camino Real, Suite 250, San Diego, CA, USA, 92130
MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.
Executives
Taheer Datoo director 181 BAY STREET, SUITE 4200, TORONTO A6 M5J 2T3
James P Flynn director 41 HARRIS CT, DANVILLE CA 94526
Sujay Kango director 1028 CHAMBERS COURT, BRIDGEWATER NJ 08807
Richard G Ghalie officer: Chief Medical Officer C/O FAVRILLE, INC, 10445 PACIFIC CENTER COURT, SAN DIEGO CA 92121
Bruce Ross Winson 10 percent owner 5950 BERKSHIRE LANE, SUITE 510, DALLAS TX 75225
Anson Funds Management Lp 10 percent owner 16000 DALLAS PARKWAY, SUITE 800, DALLAS TX 75248
Anson Management Gp Llc 10 percent owner 16000 DALLAS PARKWAY, SUITE 800, DALLAS TX 75248
Anson Advisors Inc. 10 percent owner 155 UNIVERSITY AVENUE, SUITE 207, TORONTO A6 M5H 3B7
Funicular Funds, Lp 10 percent owner 2261 MARKET STREET, #4307, SAN FRANCISCO CA 94114
Amin Nathoo 10 percent owner 155 UNIVERSITY AVENUE, SUITE 207, TORONTO Z4 M5H 3B7
Moez Kassam 10 percent owner 111 PETER STREET, SUITE 904, TORONTO A6 M5V2H1
Justin J. File officer: CFO and Corporate Secretary C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO CA 92130
Jacob Ma-weaver 10 percent owner 2261 MARKET STREET, #4307, SAN FRANCISCO CA 94114
Cable Car Capital Llc 10 percent owner 2261 MARKET STREET #4307, SAN FRANCISCO CA 94114
Baltic Charles V. Iii director C/O MARSHALL EDWARDS, INC., 11975 EL CAMINO REAL, SUITE 101, SAN DIEGO CA 92130